Education
About Us
Working with TipRanks
Follow Us
Immatics (IMTX)
NASDAQ:IMTX
IMTX Stock Chart & Stats
$9.92
<$0.01(0.14%)
At close: 4:00 PM EST
$9.92
<$0.01(0.14%)
Day’s Range― - ―
52-Week Range$3.30 - $12.41
Previous CloseN/A
Volume408.80K
Average Volume (3M)613.03K
Market Cap
$1.35B
Enterprise Value$548.73M
Total Cash (Recent Filing)$430.84M
Total Debt (Recent Filing)$16.38M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Mar 25, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding134,063,830
10 Day Avg. Volume634,493
30 Day Avg. Volume613,034
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)1.30
Price to Sales (P/S)4.79
P/FCF Ratio-4.28
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue6.47
Enterprise Value/Gross Profit6.47
Enterprise Value/Ebitda-5.16
Forecast
1Y Price Target
$16.60Price Target Upside67.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.89
Revenue Forecast (FY)$46.90M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyIMTX's TCR bispecifics, IMA402 and IMA401, have shown impressive clinical proof-of-concept with strong efficacy results.
Company StrategyAnalyst's recommendation remains OP-rated on IMTX, reflecting confidence in the company's strategy and potential for significant upside.
Safety ProfileThe safety profile for IMTX's lead TCR bispecific candidates IMA402 and IMA401 is favorable, with no high-grade adverse events reported after dose optimization.
Bears Say
Adverse Event RateThe 18.8% grade 3 CRS rate will be something to watch in upcoming phase 2 trials in uveal melanoma.
Immatics News
IMTX FAQ
What was Immatics’s price range in the past 12 months?
Immatics lowest stock price was $3.30 and its highest was $12.41 in the past 12 months.
What is Immatics’s market cap?
Immatics’s market cap is $1.35B.
When is Immatics’s upcoming earnings report date?
Immatics’s upcoming earnings report date is Mar 25, 2026 which is in 96 days.
How were Immatics’s earnings last quarter?
Immatics released its earnings results on Nov 17, 2025. The company reported -$0.492 earnings per share for the quarter, missing the consensus estimate of -$0.438 by -$0.054.
Is Immatics overvalued?
According to Wall Street analysts Immatics’s price is currently Undervalued.
Does Immatics pay dividends?
Immatics does not currently pay dividends.
What is Immatics’s EPS estimate?
Immatics’s EPS estimate is -0.48.
How many shares outstanding does Immatics have?
Immatics has 134,063,830 shares outstanding.
What happened to Immatics’s price movement after its last earnings report?
Immatics reported an EPS of -$0.492 in its last earnings report, missing expectations of -$0.438. Following the earnings report the stock price went down -7.157%.
Which hedge fund is a major shareholder of Immatics?
Currently, no hedge funds are holding shares in IMTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immatics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.60 (67.34% Upside)
$16.60 (67.34% Upside)
Blogger Sentiment
Bullish
IMTX Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 110.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 4.3%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.78%
12-Months-Change
Fundamentals
Return on Equity
-29.01%
Trailing 12-Months
Asset Growth
-5.42%
Trailing 12-Months
Company Description
Immatics
Immatics (IMTX) is a biotechnology company focused on developing innovative T cell-directed therapies for cancer treatment. The company specializes in the discovery and development of T cell engager and adoptive cell therapy products, leveraging its proprietary technology platforms to identify and target tumor-associated antigens. Immatics aims to improve patient outcomes by harnessing the power of the immune system to specifically attack cancer cells while sparing healthy tissues.
IMTX Stock 12 Month Forecast
Average Price Target
$16.60
▲(67.34% Upside)
Technical Analysis
Ownership Overview
―
Insiders
11.92% Mutual Funds
58.73% Other Institutional Investors
29.09% Public Companies and
Individual Investors